FoRx: A broader look at DNA damage repair
FoRx is using synthetic lethality to attack a broad set of cancers with new DNA damage repair targets
University of Geneva spinout FoRx debuted this week with €10 million in seed funding, a trio of strategic investors, and a new approach to synthetic lethality that could expand the cancer-killing mechanism to a broad range of tumors.
The seed round announced on Wednesday was led by M Ventures, Novartis Venture Fund and Omega Funds. Pfizer Ventures and Life Science Partners also participated.
FoRx Therapeutics AG was formed around the discovery by University of Geneva professors Thanos Halazonetis and